1.Lipton, RB, Stewart, WF, Stone, AM, Lainez, MJ, Sawyer, JP, Disability in Strategies of Care Study, group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.[see comment]. JAMA. 2000;284:2599–605.
2.Lipton, RB, Baggish, JS, Stewart, WF, Codispoti, JR, Fu, M.Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000;160:3486–92.
3.Prior, MJ, Codispoti, JR, Fu, M.A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache. Headache. 2010;50:819–33.
4.Hamalainen, ML, Hoppu, K, Valkeila, E, Santavuori, P.Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103–7.
5.Larsen, BH, Christiansen, LV, Andersen, B, Olesen, J.Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand. 1990;81:464–7.
6.Ottani, A, Leone, S, Sandrini, M, Ferrari, A, Bertolini, A.The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol. 2006;531:280–1.
7.Cooke, LJ, Becker, WJ.Migraine prevalence, treatment and impact: the canadian women and migraine study. Can J neurol Sci. 2010; 37:580–7.
8.Suthisisang, C, Poolsup, N, Kittikulsuth, W, Pudchakan, P, Wiwatpanich, P.Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007;41:1782–91.
9.Rabbie, R, Derry, S, Moore, RA, McQuay, HJ.Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008039.
10.Diener, HC, Bussone, G, de Liano, H, et al.Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24:947–54.
11.Suthisisang, C, Poolsup, N, Suksomboon, N, Lertpipopmetha, V, Tepwitukgid, B.Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010;50:808–18.
12.Derry, S, Rabbie, R, Moore, RA.Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2012;2:008783.
13.Diener, HC, Montagna, P, Gacs, G, et al.Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006;26:537–47.
14.Kirthi, V, Derry, S, Moore, RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;4:008041.
15.Lampl, C, Voelker, M, Diener, HC.Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–12.
16.Shields, KG, Goadsby, PJ.Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis. 2006;23:491–501.
17.Loder, E.Triptan therapy in migraine. N Engl J Med. 2010;363: 63–70.
18.Goldstein, DJ, Roon, KI, Offen, WW, et al.Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:1230–4.
19.Ferrari, MD, Goadsby, PJ, Roon, KI, Lipton, RB.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.[see comment][erratum appears in Cephalalgia. 2003 Feb;23(1):71.]. Cephalalgia. 2002;22:633–58.
20.Cady, RK, Freitag, FG, Mathew, NT, et al.Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache. 2009;49:350–63.
21.Bigal, ME, Serrano, D, Buse, D, Scher, A, Stewart, WF, Lipton, RB.Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–68.
22.Anonymous Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991;325:316–21.
23.Gawel, MJ, Worthington, I, Maggisano, A.A systematic review of the use of triptans in acute migraine.[see comment]. [Review] [74 refs]. Can J Neurol Sci. 2001;28:30–41.
24.Tfelt-Hansen, P, De Vries, P, Saxena, PRTriptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–87.
25.Gladstone, JP, Gawel, M.Newer formulations of the triptans: advances in migraine management. [Review] [116 refs]. Drugs. 2003;63:2285–305.
26.Rapoport, AM, Tepper, SJ, Bigal, ME, Sheftell, FD.The triptan formulations : how to match patients and products. [Review] [75 refs]. CNS Drugs. 2003;17:431–47.
27.Dodick, DW, Lipton, RB, Ferrari, MD, et al.Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. [Review] [41 refs]. Curr Pain Headache Rep. 2004;8:435–42.
28.Ferrari, MD.Current perspectives on effective migraine treatments: are small clinical differences important for patients? [Review] [9 refs]. Med Actual. 2003;39:37–41.
29.Gawel, M, Aschoff, J, May, A, Charlesworth, BR, REALIZE Study T. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from phase 1 of the REALIZE Study. Headache. 2005;45:7–16.
30.Tfelt-Hansen, P.Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia. 1993;13: 238–44.
31.Dodick, D, Brandes, J, Elkind, A, Mathew, N, Rodichok, L.Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs. 2005;19:125–36.
32.Dodick, DW, Sandrini, G, Williams, P.Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21:73–82.
33.Dodick, D, Lipton, RB, Martin, V, et al.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. [Review] [66 refs]. Headache. 2004; 44:414–25.
34.Modgill, G, Jette, N, Wang, JL, Becker, WJ, Patten, SB.A population-based longitudinal community study of major depression and migraine. Headache. 2012;52:422–32.
35.Jelinski, SE, Magnusson, JE, Becker, WJ, CHORd Study G. Factors associated with depression in patients referred to headache specialists. Neurology. 2007;68:489–95.
36.Wenzel, RG, Tepper, S, Korab, WE, Freitag, F.Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: is the FDA’s alert warranted? Ann Pharmacother. 2008;42:1692–6.
37.Evans, RW, Tepper, SJ, Shapiro, RE, Sun-edelstein, C, Tietjen, GE.The FdA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50: 1089–99.
38.Soldin, OP, Tonning, JM; Obstetric-Fetal Pharmacology Research Unit Network. Serotonin syndrome associated with triptan monotherapy. N Engl J Med. 2008 May 15;358(20):2185–6.
39.Headache Classification Subcommittee of the International Headache, Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24:9–160.
40.Yates, R, Sorensen, J, Bergstrom, M, et al.Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia. 2005;25:1103–9.
41.Charlesworth, BR, Dowson, AJ, Purdy, A, Becker, WJ, Boes-Hansen, S, Farkkila, M.Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:653–67.
42.Ahrens, SP, Farmer, MV, Williams, DL, et al.Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999;19:525–30.
43.Aurora, S, Kori, S, Barrodale, P, Nelsen, A, McDonald, S.Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443–6.
44.Aurora, SK, Kori, SH, Barrodale, P, McDonald, SA, Haseley, D.Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46:57–63.
45.Johannes, CB, Varas-Lorenzo, C, McQuay, LJ, Midkiff, KD, Fife, D.Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol drug Saf. 2010;19:881–8.
46.Van Noord, C, Dieleman, JP, van Herpen, G, Verhamme, K, Sturkenboom, MC.Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Safety. 2010;33:1003–14.
47.Tokola, RA.The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia. 1988;8:139–47.
48.Tokola, RA, Neuvonen, PJ.Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol. 1984;17:67–75.
49.Volans, GN.The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975;2: 57–63.
50.MacGregor, EA, Wilkinson, M, Bancroft, K.Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993;13: 124–7.
51.Schulman, EA, Dermott, KF.Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. [see comment]. Headache. 2003;43:729–33.
52.Ferrari, MD, James, MH, Bates, D, et al.Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14:330–8.
53.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:1443–54.
54.Geraud, G, Keywood, C, Senard, JM.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376–88.
55.Winner, P, Ricalde, O, Le Force, B, Saper, J, Margul, B.A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. [see comment]. Arch Neurol. 1996;53:180–4.
56.Teall, J, Tuchman, M, Cutler, N, et al.Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache. 1998;38:281–7.
57.Tepper, SJ, Donnan, GA, Dowson, AJ, et al.A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin. 1999;15:254–71.
58.Sheftell, F, Ryan, R, Pitman, V, Eletriptan Steering, C.Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003;43:202–13.
59.Rapoport, AM, Ramadan, NM, Adelman, JU, et al.Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:1210–8.
60.Bates, D, Ashford, E, Dawson, R, et al.Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44:1587–92.
61.Olesen, J, Diener, HC, Schoenen, J, Hettiarachchi, J.No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:671–7.
62.Dowson, A.Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur Neurol. 1996;36:28–31.
63.Aurora, SK, Barrodale, PM, McDonald, SA, Jakubowski, M, Burstein, R.Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache. 2009;49:1001–4.
64.Artto, V, nissila, M, Wessman, M, Palotie, A, Farkkila, M, Kallela, M.Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14:1053–6.
65.Klapper, J, Mathew, N, Nett, R.Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41: 981–4.
66.Brandes, JL, Kudrow, D, Stark, SR, et al.Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007; 297:1443–54.
67.Smith, TR, Sunshine, A, Stark, SR, Littlefield, DE, Spruill, SE, Alexander, WJ.Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983–91.
68.Mathew, NT, Landy, S, Stark, S, et al.Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49:971–82
69.Silberstein, SD, Mannix, LK, Goldstein, J, et al.Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008;71:114–21.
70.Krymchantowski, AV.Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58:428–30.
71.Jakubowski, M, Levy, D, Goor-Aryeh, I, Collins, B, Bajwa, Z, Burstein, R.Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005;45:850–61.
72.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52:467–82.
73.Turkewitz, LJ, Casaly, JS, Dawson, GA, Wirth, O, Hurst, RJ, Gillette, PL.Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992;32:452–4.
74.Sandrini, G, Cerbo, R, Del Bene, E, et al.Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. Int J Clin Pract. 2007;61:1256–69.
75.Di Monda, V, Nicolodi, M, Aloisio, A, et al.Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache. 2003;43:835–44.
76.Kelley, NE, Tepper, DE.Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012;52: 292–306.
77.Jones, EB, Gonzalez, ER, Boggs, JG, Grillo, JA, Elswick, RK Jr., Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24:237–41.
78.McEwen, JI, O’Connor, HM, Dinsdale, HB.Treatment of migraine with intramuscular chlorpromazine. Ann Emerg Med. 1987;16: 758–63.
79.Rozen, TD.Migraine headache: immunosuppressant therapy. Curr Treat Options Neurol. 2002;4:395–401.
80.Colman, I, Friedman, BW, Brown, MD, et al.Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359–61.
81.Taheraghdam, AA, Amiri, H, Shojaan, H, Shamsvahdati, S, Houshyar, Y.Intravenous dexamethasone versus morphine in relieving of acute migraine headache. Pak J Biol Sci. 2011;14:682–7.
82.Bigal, M, Sheftell, F, Tepper, S, Tepper, D, Ho, TW, Rapoport, A.A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache. 2008;48: 1286–93.
83.Boureau, F, Joubert, JM, Lasserre, V, Prum, B, Delecoeuillerie, G.Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia. 1994;14:156–61.
84.Ho, TW, Rodgers, A, Bigal, ME.Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49:395–403.
85.Bigal, ME, Lipton, RB.Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821–8.
86.De Felice, M, Porreca, F.Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009;29: 1277–84.
87.Madadi, P, Koren, G.Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008;9:1267–84.
88.Grond, S, Sablotzki, A.Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.
89.Tepper, SJ.Medication-overuse headache. CONTINUUM: Lifelong Learning in Neurology. 2012;18:807–22.
90.Fisher, MA, Glass, S.Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 1997;48: 1156–60.
91.Bigal, ME, Lipton, RB.Acute treatment of migraine headache. Curr Treat Options neurol. 2003;5:423–30.
92.Gerhardt, RT, Hermstad, E, Crawford, DM, Rayfield, J, Pfaff, J, Hunter, CJ.Postdischarge secobarbital after ED migraine treatment decreases pain and improves resolution. Am J emerg Med. 2011;29:86–90.
93.Silberstein, SD, McCrory, DC.Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144–66.
94.Lipton, RB.Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37:S33–41.
95.Tfelt-Hansen, P, Saxena, PR, dahlof, C, et al.Ergotamine in the acute treatment of migraine: a review and european consensus. [Review] [84 refs]. Brain. 2000;123:9–18.
96.Baron, EP, Tepper, SJ.Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50:1353–61.
97.Bigal, ME, Tepper, SJ.Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003;7:55–62.
98.MaassenVandenBrink, A, Reekers, M, Bax, WA, Ferrari, MD, Saxena, PR.Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25–30.
99.Hoskin, KL, Kaube, H, Goadsby, PJ.Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996;119:249–56.
100.Becker, WJ, Riess, CM, Hoag, J.Effectiveness of subcutaneous dihydroergotamine by home injection for migraine. Headache. 1996;36:144–8.
101.Weisz, MA, El-Raheb, M, Blumenthal, HJ.Home administration of intramuscular DHE for the treatment of acute migraine headache. Headache. 1994;34:371–3.
102.Klapper, JA, Stanton, J.Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992;32:21–3.
103.Rothrock, JF.Patient information regarding subcutaneous selfadministration of dihydroergotamine (DHE). Headache. 2007;47:740.
104.Raskin, NH.Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.
105.Silberstein, SD, Schulman, EA, Hopkins, MM.Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334–9.
106.Eadie, MJ.Ergot of rye-the first specific for migraine. J Clin Neurosci. 2004;11:4–7.
107.Schmidt, R, Fanchamps, A.Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7:213–6.
108.Evers, S, Gralow, I, Bauer, B, et al.Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin Neuropharmacol. 1999;22:201–6.
109.Dahlof, C.Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. [Review] [18 refs]. Cephalalgia. 1993;13:166–71.
110.Diener, HC, Pfaffenrath, V, Pageler, L, Peil, H, Aicher, B.The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2005;25:776–87.
111.Diener, HC, Peil, H, Aicher, B.The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2011;31:1466–76.
112.Laska, EM, Sunshine, A, Mueller, F, Elvers, WB, Siegel, C, Rubin, A.Caffeine as an analgesic adjuvant. JAMA. 1984;251:1711–8.
113.Ray, WA, Varas-Lorenzo, C, Chung, CP, et al.Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circulation. Circ Cardiovasc Qual Outcomes. 2009;2:155–63.
114.Fosbol, EL, Folke, F, Jacobsen, S, et al.Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circulation. Circ Cardiovasc Qual Outcomes. 2010;3:395–405.
115.Sauro, KM, Becker, WJ.Multidisciplinary treatment for headache in the Canadian healthcare setting. Can J Neurol Sci. 2008;35:46–56.
116.MacGregor, EA, Victor, TW, Hu, X, et al.Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache. 2010;50:528–38.
117.Diamond, ML, Cady, RK, Mao, L, et al.Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache. 2008;48:248–58.
118.Mannix, LK, Loder, E, nett, R, et al.Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007;27:414–21.
119.Tuchman, M, Hee, A, Emeribe, U, Silberstein, S.Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006;20:1019–26.
120.Pringsheim, T, Davenport, WJ, Dodick, D.Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008;70:1555–63.
121.Mannix, LK, Martin, VT, Cady, RK, et al.Combination treatment for menstrual migraine and dysmenorrhea using sumatriptannaproxen: two randomized controlled trials. Obstet Gynecol. 2009;114:106–13.
122.Brandes, JL, Poole, A, Kallela, M, et al.Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29:1133–48.
123.Silberstein, SD, Elkind, AH, Schreiber, C, Keywood, C.A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261–9.
124.Tuchman, MM, Hee, A, Emeribe, U, Silberstein, S.Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008;22:877–86.
125.Mannix, LK, Savani, N, Landy, S, et al.Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache. 2007;47:1037–49.
126.Sances, G, Martignoni, E, Fioroni, L, Blandini, F, Facchinetti, F, nappi, G.Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705–9.
127.MacGregor, EA, Frith, A, Ellis, J, Aspinall, L, Hackshaw, A.Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67:2159–63.
128.Almen-Christensson, A, Hammar, M, Lindh-Astrand, L, Landtblom, AM, Brynhildsen, J.Prevention of menstrual migraine with perimenstrual transdermal 17-beta-estradiol: a randomized, placebo-controlled, double-blind crossover study. Fertil Steril. 2011;96:498–500.e1.
129.Facchinetti, F, Sances, G, Borella, P, Genazzani, AR, Nappi, G.Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298–301.
130.Al-Waili, NS.Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000;5:176–82.
131.Teichmann, A, Apter, D, Emerich, J, et al.Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009;80:504–11.
132.Reid, RL, Fortier, MP, Smith, L, Mirkin, S, Grubb, GS, Constantine, GD.Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010;82:497–502.
133.Coffee, AL, Sulak, PJ, Kuehl, TJ.Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception. 2007;75:444–9.
134.Sulak, P, Willis, S, Kuehl, T, Coffee, A, Clark, J.Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27–37.
135.Loder, E, Rizzoli, P, Golub, J.Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:329–40.
136.Calhoun, A.Combined hormonal contraceptives: is it time to reassess their role in migraine? Headache. 2012;52:648–60.
137.MacGregor, EA.Contraception and headache. Headache. 2013;53:247–76.
138.Macintyre, PE, Schug, SA, Scott, DA, Visser, EJ, Walker, SM, APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute pain management: scientific evidence. Melbourne: ANZA and FPM, 2010.
139.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Effects of codeine on pregnancy outcome: Results from a large population-based cohort study. Eur J Clin Pharmacol. 2011;67:1253–61.
140.Nezvalova-Henriksen, K, Spigset, O, Nordeng, H.Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the norwegian Mother and Child Cohort Study. Headache. 2010;50:563–75.
141.Duong, S, Bozzo, P, Nordeng, H, Einarson, A.Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician. 2010;56:537–9.
142.American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.
143.Hendrickson, RG, McKeown, NJ.Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012;50:1–14.
144.Rossi, P, Ambrosini, A, Buzzi, MG.Prodromes and predictors of migraine attack. Funct Neurol. 2005;20:185–91.
145.Kelman, L.The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:865–72.
146.Schoonman, GG, Evers, DJ, Terwindt, GM, van Dijk, JG, Ferrari, MD.The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia. 2006;26:1209–13.
147.Quintela, E, Castillo, J, Munoz, P, Pascual, J.Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia. 2006;26:1051–60.
148.Giffin, NJ, Ruggiero, L, Lipton, RB, et al.Premonitory symptoms in migraine: an electronic diary study. Neurology 2003;60:935–40.
149.Waelkens, J.Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984;4:85–90.
150.Luciani, R, Carter, D, Mannix, L, Hemphill, M, Diamond, M, Cady, R.Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000;20:122–6.
151.Waelkens, J.Domperidone in the prevention of complete classical migraine. Br Med J (Clin Res ed). 1982;284:944.
152.Becker, WJ.The premonitory phase of migraine and migraine management. Cephalalgia. 2012 Feb 15;[epub ahead of print].
153.Jelinski, SE, Becker, WJ, Christie, SN, et al.Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada. Cephalalgia. 2006;26:578–88.
154.Derry, S, Moore, RA, McQuay, HJ.Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;008040.
155.Lipton, RB, Grosberg, B, Singer, RP, et al.Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010;30:1336–45.
156.Buchan, P, Keywood, C, Wade, A, Ward, C.Clinical pharmacokinetics of frovatriptan. Headache. 2002;42:S54–62.
157.Johnston, MM, Rapoport, AM.Triptans for the management of migraine. Drugs. 2010;70:1505–18.
158.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane database Syst Rev. 2012;2:009665.
159.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:009663.
160.Pascual, J, Falk, RM, Piessens, F, et al.Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588–96.
161.Rapoport, A, Ryan, R, Goldstein, J, Keywood, C.Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002;42:S74–83.
162.Derry, CJ, Derry, S, Moore, RA.Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:008615.
163.Pryse-Phillips, WE, Dodick, DW, Edmeads, JG, et al.Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. [see comment][erratum appears in CMAJ 1997 Nov 15;157(10):1354]. [Review] [160 refs]. CMAJ. 1997;156:1273–87.